242 related articles for article (PubMed ID: 9674399)
1. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
[TBL] [Abstract][Full Text] [Related]
3. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
4. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
[TBL] [Abstract][Full Text] [Related]
5. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
Carretero-Margolis CD; Fivenson DP
J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
9. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Kazin R; Bujanauskas P; Vonderheid EC
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
[No Abstract] [Full Text] [Related]
10. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
11. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
12. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
[TBL] [Abstract][Full Text] [Related]
13. Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases.
Buder K; Müller PA; Beckmann G; Ugurel S; Bröcker EB; Becker JC
Acta Derm Venereol; 2014 Jan; 94(1):94-6. PubMed ID: 23756575
[No Abstract] [Full Text] [Related]
14. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
15. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
Assaf C
Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
[No Abstract] [Full Text] [Related]
16. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Prince HM; Martin AG; Olsen EA; Fivenson DP; Duvic M
Leuk Lymphoma; 2013 Jan; 54(1):69-75. PubMed ID: 22738414
[TBL] [Abstract][Full Text] [Related]
17. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
[TBL] [Abstract][Full Text] [Related]
18. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
[TBL] [Abstract][Full Text] [Related]
19. Interleukins in the treatment of mycosis fungoides.
Gerami P; Guitart J; Rosen S; Kuzel TM
G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
[TBL] [Abstract][Full Text] [Related]
20. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
